Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VRINO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
sYS6043
|
|||||
| Synonyms |
SYS6043
Click to Show/Hide
|
|||||
| Organization |
CSPC Pharmaceutical Group (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-B7H3 antibody
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276); Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
JS-1
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
JSSW-001
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||||
| Lung cancer |
1 Trials
|
||||||||||
| Ovarian cancer |
1 Trials
|
||||||||||
| Prostate cancer |
1 Trials
|
||||||||||
| Unspecific solid tumor |
1 Trials
|
1 Trials
|